Jeremiah John Andersen
Physician at Baier Ln, La Crosse, WI
License number
Colorado 56105
Issued Date
Dec 3, 2015
Renew Date
Dec 3, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
2945 Baier Ln #LA, La Crosse, WI 54601
Professional information
Dr. Jeremiah J Andersen, La Crosse WI - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Age:
50
Address:
1836 South Ave, La Crosse 54601
(608) 782-7300 (Phone), (608) 785-2181 (Fax)
Gundersen Lutheran La Crosse
1836 South Ave, La Crosse 54601
(608) 782-7300 (Phone)
(608) 782-7300 (Phone), (608) 785-2181 (Fax)
Gundersen Lutheran La Crosse
1836 South Ave, La Crosse 54601
(608) 782-7300 (Phone)
Certifications:
Anatomic & Clinical Pathology, 2007
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Ia Roy J & L Carver Com
Graduated: 2001
University of Ia Roy J & L Carver Com
Graduated: 2001
Reagents, Methods, And Kits For The Classification Of Cancer
US Patent:
2013025, Oct 3, 2013
Filed:
Apr 2, 2013
Appl. No.:
13/855365
Inventors:
Steven E. Cash - La Crosse WI, US
Jeremiah J. Andersen - La Crosse WI, US
Qiangwei Fu - La Crosse WI, US
Jeremiah J. Andersen - La Crosse WI, US
Qiangwei Fu - La Crosse WI, US
Assignee:
Gundersen Lutheran Health System - La Crosse WI
International Classification:
G01N 33/68
US Classification:
4241741, 435 723
Abstract:
Reagents, methods, and kits for the classification of cancer that comprise or employ antibodies that bind specific regions of CD43. One method includes contacting tissue with an antibody capable of specifically binding the cytoplasmic tail of CD43, contacting the tissue with an antibody capable of specifically binding the extracellular domain of CD43, and resolving cellular localization of any binding to the tissue with the antibody capable of specifically binding the cytoplasmic tail of CD43 and the antibody capable of specifically binding the extracellular domain of CD43. The binding patterns of the antibodies can be used to characterize cancer as more aggressive or less aggressive and can distinguish small cell lung cancer from non-small cell lung cancer. The cancer may therefore be treated in accordance of the characterization.